Your browser doesn't support javascript.
loading
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Buisseret, L; Pommey, S; Allard, B; Garaud, S; Bergeron, M; Cousineau, I; Ameye, L; Bareche, Y; Paesmans, M; Crown, J P A; Di Leo, A; Loi, S; Piccart-Gebhart, M; Willard-Gallo, K; Sotiriou, C; Stagg, J.
  • Buisseret L; Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada; Molecular Immunology Unit, Brussels, Belgium; Breast Cancer Translational Research Laboratory J-C Heuson, Brussels, Belgium.
  • Pommey S; Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
  • Allard B; Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
  • Garaud S; Molecular Immunology Unit, Brussels, Belgium.
  • Bergeron M; Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
  • Cousineau I; Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
  • Ameye L; Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Bareche Y; Breast Cancer Translational Research Laboratory J-C Heuson, Brussels, Belgium.
  • Paesmans M; Data Centre, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Crown JPA; Medical Oncology, Vincent's University Hospital, Dublin, Ireland.
  • Di Leo A; Medical Oncology Department, Hospital of Prato, Prato, Italy.
  • Loi S; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Piccart-Gebhart M; Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
  • Willard-Gallo K; Molecular Immunology Unit, Brussels, Belgium.
  • Sotiriou C; Breast Cancer Translational Research Laboratory J-C Heuson, Brussels, Belgium.
  • Stagg J; Research Centre, University of Montreal Hospital, Montréal, Canada; Montreal Cancer Institute, Montréal, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, Canada. Electronic address: john.stagg@umontreal.ca.
Ann Oncol ; 29(4): 1056-1062, 2018 04 01.
Article en En | MEDLINE | ID: mdl-29145561
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: 5'-Nucleotidasa / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: 5'-Nucleotidasa / Neoplasias de la Mama Triple Negativas Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Año: 2018 Tipo del documento: Article